Skip to main content
SpringerLink
Log in

Preparation of a Heat-Shock Protein 70-Based Vaccine from DC–Tumor Fusion Cells

  • Protocol
  • First Online:
Book cover Molecular Chaperones

Part of the book series: Methods in Molecular Biology ((MIMB,volume 787))

Abstract

We have developed an enhanced molecular chaperone-based vaccine through rapid isolation of heat-shock protein 70 peptide complexes (Hsp70.PC) after the fusion of tumor and dendritic cells (DCs) (Hsp70.PC-F). In this approach, the tumor antigens are introduced into the antigen-processing machinery of dendritic cells through the cell fusion process and, thus, we can obtain antigenic tumor peptides or their intermediates that have been processed by dendritic cells. Our results show that Hsp70.PC-F has increased immunogenicity compared to preparations from tumor cells alone and, therefore, constitutes an improved formulation of chaperone protein-based tumor vaccine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lindquist S., Craig E. A. (1988) The heat shock proteins. Ann. Rev. Genet. 22, 631–7.

    Article  PubMed  CAS  Google Scholar 

  2. Georgopolis C., Welch W. J. (1993) Role of the major heat shock proteins as molecular chaperones Ann. Rev. Cell Biol. 9, 601–34.

    Article  Google Scholar 

  3. Bukau B., Horwich A. L. (1998) The Hsp70 and Hsp60 chaperone machines Cell 92, 351–66.

    Article  PubMed  CAS  Google Scholar 

  4. Tang D., Khaleque A. A., Jones E. R., Theriault J. R., Li C., Wong W. H., Stevenson M. A., et al. (2005) Expression of heat shock proteins and HSP messenger ribonucleic acid in human prostate carcinoma in vitro and in tumors in vivo. Cell Stress Chaperones 10, 46–58.

    Google Scholar 

  5. Noessner E., Gastpar R., Milani V., Brandl A., Hutzler P. J., Kuppner M. C., Roos M., et al. (2002) Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells J Immunol 169, 5424–32.

    PubMed  CAS  Google Scholar 

  6. Srivastava P. K., Amato R. J. (2001) Heat shock proteins: the “Swiss Army Knife” vaccines against cancers and infectious agents Vaccine 19, 2590–7.

    Article  PubMed  CAS  Google Scholar 

  7. Nylandsted J., Brand K., and Jaattela M. (2000) Heat shock protein 70 is required for the survival of cancer cells Ann N Y Acad Sci 926, 122–5.

    Article  PubMed  CAS  Google Scholar 

  8. Cornford P. A., Dodson A. R., Parsons K. F., Desmond A. D., Woolfenden A., Fordham M., Neoptolemos J. P., et al. (2000) Heat shock protein expression independently predicts clinical outcome in prostate cancer Cancer Res 60, 7099–105.

    PubMed  CAS  Google Scholar 

  9. Clark P. R., Menoret A. (2001) The inducible Hsp70 as a marker of tumor immunogenicity Cell Stress Chaperones 6, 121–5.

    Article  PubMed  CAS  Google Scholar 

  10. Srivastava P. (2002) Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses Annu Rev Immunol 20, 395–425.

    Article  PubMed  CAS  Google Scholar 

  11. Srivastava P. (2003) Hypothesis: controlled necrosis as a tool for immunotherapy of human cancer. Cancer Immun. 3, 4.

    PubMed  Google Scholar 

  12. Srivastava P. K. (2000) Immunotherapy of human cancer: lessons from mice Nat Immunol 1, 363–6.

    Article  PubMed  CAS  Google Scholar 

  13. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M. R., Gallino G., et al. (2002) Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings J Clin Oncol 20, 4169–80.

    Article  PubMed  CAS  Google Scholar 

  14. Mazzaferro V., Coppa J., Carrabba M. G., Rivoltini L., Schiavo M., Regalia E., Mariani L., et al. (2003) Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer Clin Cancer Res 9, 3235–45.

    PubMed  CAS  Google Scholar 

  15. Parmiani G., De Filippo A., Pilla L., Castelli C., and Rivoltini L. (2006) Heat shock proteins gp96 as immunogens in cancer patients Int J Hyperthermia 22, 223–7.

    Article  PubMed  CAS  Google Scholar 

  16. Pilla L., Patuzzo R., Rivoltini L., Maio M., Pennacchioli E., Lamaj E., Maurichi A., et al. (2006) A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients Cancer Immunol Immunother 55, 958–68.

    Article  PubMed  CAS  Google Scholar 

  17. Testori A., Richards J., Whitman E., Mann G. B., Lutzky J., Camacho L., Parmiani G., et al. (2008) Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma: the C-100-21 Study Group J Clin Oncol 26, 955–62.

    Article  PubMed  CAS  Google Scholar 

  18. Wood C., Srivastava P., Bukowski R., Lacombe L., Gorelov A. I., Gorelov S., Mulders P., et al. (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial Lancet 372, 145–54.

    Article  PubMed  CAS  Google Scholar 

  19. Enomoto Y., Bharti A., Khaleque A. A., Song B., Liu C., Apostolopoulos V., Xing P. X., et al. (2006) Enhanced immunogenicity of heat shock protein 70 peptide complexes from dendritic cell-tumor fusion cells J Immunol 177, 5946–55.

    PubMed  CAS  Google Scholar 

  20. Steinman R. M. (1991) The dendritic cell system and its role in immunogenicity Annu Rev Immunol 9, 271–96.

    Article  PubMed  CAS  Google Scholar 

  21. Steinman R. M. (2001) Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation Mt Sinai J Med 68, 106–66.

    Google Scholar 

  22. Gong J., Chen D., Kashiwaba M., and Kufe D. (1997) Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells Nat Med 3, 558–61.

    Article  PubMed  CAS  Google Scholar 

  23. Gong J., Koido S., Chen D., Tanaka Y., Huang L., Avigan D., Anderson K., et al. (2002) Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12 Blood 99, 2512–7.

    Google Scholar 

  24. Liu Y., Zhang W., Chan T., Saxena A., and Xiang J. (2002) Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity Leuk Res 26, 757–63.

    Article  PubMed  CAS  Google Scholar 

  25. Lindner M., Schirrmacher V. (2002) Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols Eur J Clin Invest 32, 207–17.

    Article  PubMed  Google Scholar 

  26. Homma S., Toda G., Gong J., Kufe D., and Ohno T. (2001) Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice J Gastroenterol 36, 764–71.

    Article  PubMed  CAS  Google Scholar 

  27. Cao X., Zhang W., Wang J., Zhang M., Huang X., Hamada H., and Chen W. (1999) Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells Immunology 97, 616–25.

    Article  PubMed  CAS  Google Scholar 

  28. Wang J., Saffold S., Cao X., Krauss J., and Chen W. (1998) Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines J Immunol 161, 5516–24.

    PubMed  CAS  Google Scholar 

  29. Hayashi T., Tanaka H., Tanaka J., Wang R., Averbook B. J., Cohen P. A., and Shu S. (2002) Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion Clin Immunol 104, 14–20.

    Article  PubMed  CAS  Google Scholar 

  30. Xia J., Tanaka Y., Koido S., Liu C., Mukherjee P., Gendler S. J., and Gong J. (2003) Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells J Immunol 170, 1980–6.

    PubMed  CAS  Google Scholar 

  31. Kao J. Y., Gong Y., Chen C. M., Zheng Q. D., and Chen J. J. (2003) Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine J Immunol 170, 3806–11.

    PubMed  CAS  Google Scholar 

  32. Takeda A., Homma S., Okamoto T., Kufe D., and Ohno T. (2003) Immature dendritic cell/tumor cell fusions induce potent antitumour immunity Eur J Clin Invest 33, 897–904.

    Article  PubMed  CAS  Google Scholar 

  33. Zhang J. K., Li J., Zhang J., Chen H. B., and Chen S. B. (2003) Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo World J Gastroenterol 9, 479–84.

    PubMed  Google Scholar 

  34. Li J., Holmes L. M., Franek K. J., Burgin K. E., Wagner T. E., and Wei Y. (2001) Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity Cancer Immunol Immunother 50, 456–62.

    Article  PubMed  CAS  Google Scholar 

  35. Xia D., Chan T., and Xiang J. (2005) Dendritic cell/myeloma hybrid vaccine Methods Mol Med 113, 225–33.

    PubMed  CAS  Google Scholar 

  36. Homma S., Kikuchi T., Ishiji N., Ochiai K., Takeyama H., Saotome H., Sagawa Y., et al. (2005) Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12 Eur J Clin Invest 35, 279–86.

    Google Scholar 

  37. Kao J. Y., Zhang M., Chen C. M., and Chen J. J. (2005) Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer Immunol Lett 101, 154–9.

    Article  PubMed  CAS  Google Scholar 

  38. Ogawa F., Iinuma H., and Okinaga K. (2004) Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells Scand J Immunol 59, 432–9.

    Article  PubMed  CAS  Google Scholar 

  39. Akasaki Y., Kikuchi T., Homma S., Abe T., Kofe D., and Ohno T. (2001) Antitumor Effect of Immunizations With Fusions of Dendritic and Glioma Cells in a Mouse Brain Tumor Model J Immunother 24, 106–13.

    Article  CAS  Google Scholar 

  40. Scott-Taylor T. H., Pettengell R., Clarke I., Stuhler G., La Barthe M. C., Walden P., and Dalgleish A. G. (2000) Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines Biochim Biophys Acta 1500, 265–79.

    PubMed  CAS  Google Scholar 

  41. Tanaka H., Shimizu K., Hayashi T., and Shu S. (2002) Therapeutic immune response induced by electrofusion of dendritic and tumor cells Cell Immunol 220, 1–12.

    Article  PubMed  CAS  Google Scholar 

  42. Siders W. M., Vergilis K. L., Johnson C., Shields J., and Kaplan J. M. (2003) Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells Mol Ther 7, 498–505.

    Article  PubMed  CAS  Google Scholar 

  43. Jantscheff P., Spagnoli G., Zajac P., and Rochlitz C. F. (2002) Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells Cancer Immunol Immunother 51, 367–75.

    Article  PubMed  CAS  Google Scholar 

  44. Goddard R. V., Prentice A. G., Copplestone J. A., and Kaminski E. R. (2003) In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids Clin Exp Immunol 131, 82–9.

    Article  PubMed  CAS  Google Scholar 

  45. Marten A., Renoth S., Heinicke T., Albers P., Pauli A., Mey U., Caspari R., et al. (2003) Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma Hum Gene Ther 14, 483–94.

    Article  PubMed  Google Scholar 

  46. Trevor K. T., Cover C., Ruiz Y. W., Akporiaye E. T., Hersh E. M., Landais D., Taylor R. R., et al. (2004) Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application Cancer Immunol Immunother 53, 705–14.

    Article  PubMed  Google Scholar 

  47. Suzuki T., Fukuhara T., Tanaka M., Nakamura A., Akiyama K., Sakakibara T., Koinuma D., et al. (2005) Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells Clin Cancer Res 11, 58–66.

    PubMed  CAS  Google Scholar 

  48. Trefzer U., Herberth G., Wohlan K., Milling A., Thiemann M., Sharav T., Sparbier K., et al. (2005) Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results Vaccine 23, 2367–73.

    Article  PubMed  CAS  Google Scholar 

  49. Shimizu K., Kuriyama H., Kjaergaard J., Lee W., Tanaka H., and Shu S. (2004) Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy J Immunother 27, 265–72.

    Article  PubMed  CAS  Google Scholar 

  50. Phan V., Errington F., Cheong S. C., Kottke T., Gough M., Altmann S., Brandenburger A., et al. (2003) A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines Nat Med 9, 1215–9.

    Article  PubMed  CAS  Google Scholar 

  51. Hiraoka K., Yamamoto S., Otsuru S., Nakai S., Tamai K., Morishita R., Ogihara T., et al. (2004) Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides J Immunol 173, 4297–307.

    PubMed  CAS  Google Scholar 

  52. Koido S., Ohana M., Liu C., Nikrui N., Durfee J., Lerner A., and Gong J. (2004) Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation Clin Immunol 113, 261–9.

    Article  PubMed  CAS  Google Scholar 

  53. Galea-Lauri J., Darling D., Mufti G., Harrison P., and Farzaneh F. (2002) Eliciting cytotoxic T lymphocytes against acute myeloid leukemia- derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination Cancer Immunol Immunother 51, 299–310.

    Article  PubMed  CAS  Google Scholar 

  54. Gong J., Nikrui N., Chen D., Koido S., Wu Z., Tanaka Y., Cannistra S., et al. (2000) Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity J Immunol 165, 1705–11.

    PubMed  CAS  Google Scholar 

  55. Gong J., Avigan D., Chen D., Wu Z., Koido S., Kashiwaba M., and Kufe D. (2000) Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells Proc Natl Acad Sci USA 97, 2715–8.

    Article  PubMed  CAS  Google Scholar 

  56. Koido S., Nikrui N., Ohana M., Xia J., Tanaka Y., Liu C., Durfee J. K., et al. (2005) Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use Gynecol Oncol 99, 462–71.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Boston University School of Medicine, Boston, MA, USA

    Desheng Weng & Jianlin Gong

  2. Molecular and Cellular Radiation Oncology, Department of Radiation Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Stuart K. Calderwood

Authors
  1. Desheng Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stuart K. Calderwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jianlin Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianlin Gong .

Editor information

Editors and Affiliations

  1. Beth Israel Deaconess Medical Center, Department of Radiation Oncology, Harvard Medical School, Brookline Ave 330, Boston, 02215, Massachusetts, USA

    Stuart K. Calderwood

  2. National Cancer Institute, Urologic Oncology Branch, National Institutes of Health, Rockville Pike 9000, Bethesda, 20814, Maryland, USA

    Thomas L. Prince

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this protocol

Cite this protocol

Weng, D., Calderwood, S.K., Gong, J. (2011). Preparation of a Heat-Shock Protein 70-Based Vaccine from DC–Tumor Fusion Cells. In: Calderwood, S., Prince, T. (eds) Molecular Chaperones. Methods in Molecular Biology, vol 787. Humana Press. https://doi.org/10.1007/978-1-61779-295-3_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-295-3_19

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-294-6

  • Online ISBN: 978-1-61779-295-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation